A Blinded, Safety, Tolerability, and Pharmacokinetic Study of Single Doses of BIIB059 in Healthy Japanese Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Apr 2018
At a glance
- Drugs BIIB 059 (Primary)
- Indications Cutaneous lupus erythematosus; Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Biogen
- 10 Apr 2018 Planned End Date changed from 29 May 2018 to 12 Jun 2018.
- 10 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 07 Nov 2017 Status changed from not yet recruiting to recruiting.